Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis

Journal of Investigative Medicine

Volumn 53, Issue 7, 2005, Pages 347-352

  Njoku, Chinedu J ^a   Patrick, Kennerly S ^b   Ruiz Jr , Philip ^c   Oates, Jim C ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Isoprostanes; Lupus nephritis; Nitric oxide synthase

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROUS OXIDE; REACTIVE OXYGEN METABOLITE;

ANALYZER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE MODEL; ENZYME INHIBITION; FEMALE; GAS CHROMATOGRAPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MASS SPECTROMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; URINALYSIS; URINE LEVEL;

ANIMALIA; MURINAE;

EID: 29144460223     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2005.53705     Document Type: Article

References (34)

1. Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. Curr Opin Rheumatol 2002;14:498-503.
2. Amoura Z, Chabre H, Koutouzov S, et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994;37:1684-8.
3. Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med 1974;134:1027-35.
4. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmunol Rev 2002;1:233-7.
5. Gescuk BD, Davis JC Jr. Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002;14:515-21.
6. Kant KS, Pollak VE, Weiss MA, et al. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore) 1981;60:71-86.
7. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L- arginine. J Exp Med 1994;179:651-60.
8. Weinberg JB. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol Res 2001;22:319-41.
9. Wanchu A, Khullar M, Deodhar SD, et al. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998;18:41-3.
10. Peters H, Border WA, Ruckert M, et al. L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 2003;63:1382-92.
11. Cattell V. Nitric oxide and glomerulonephritis. Semin Nephrol 1999;19:277-87.
12. Montuschi P, Ciabattoni G, Paredi R et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998;158(5 Pt 1):1524-7.
13. Khan J, Brennan DM, Bradley N, et al. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 1998;330(Pt2):795-801.
14. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997;36:1-21.
15. Morrow JD, Minton TA, Roberts LJD. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992;44:155-63.
16. Morrow JD, Roberts LJ II. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996;51:1-9.
17. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 2003;5:383-90.
18. Kovacic P, Jacintho JD. Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: unifying theme of oxidative stress. Mini Rev Med Chem 2003;3:568-75.
19. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-86.
20. Morrow JD, Zackert WE, Yang JP, et al. Quantification of the major urinary metabolite of 15-F-2t-isoprostane (8-iso-PGF(2 alpha)) by a stable isotope dilution mass spectrometric assay. Anal Biochem 1999;269:326-31.
21. Ames PR, Alves J, Murat I, et al. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999;38:529-34.
22. Venkataraman S, Martin SM, Schafer FQ, Buettner GR. Detailed methods for the quantification of nitric oxide in aqueous solutions using either an oxygen monitor or EPR. Free Radic Biol Med 2000;29:580-5.
23. Mayhan WG, Sharpe GM, Anding P. Agonist-induced release of nitric oxide during acute exposure to nicotine. Life Sci 1999;65:1829-37.
24. Wu CC, Yen MH. Higher level of plasma nitric oxide in spontaneously hypertensive rats. Am J Hypertens 1999;12:476-82.
25. Fam SS, Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr Med Chem 2003;10:1723-40.
26. Tsikas D, Schwedhelm E, Suchy MT, et al. Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J Chromatogr B Analyt Technol Biomed Life Sci 2003;794:237-55.
27. Oates JC, Ruiz P, Alexander A, et al. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 1997;83:86-92.
28. Reilly CM, Farrelly LW, Viti D, et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 2002;61:839-46.
29. Ramsey KH, Sigar IM, Rana SV, et al. Inducible nitric oxide synthase regulates production of isoprostanes in vivo during chlamydial genital infection in mice. Infect Immun 2003;71:7183-7.
30. Marnett LJ, Wright TL, Crews BC, et al. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric oxide synthase. J Biol Chem 2000;275:13427-30.
31. Matejovic M, Krouzecky A, Martinkova V, et al. Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 2004;21:458-65.
32. Binder CJ, Weiher H, Exner M, Kerjaschki D. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: a model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 1999;154:1067-75.
33. Budisavljevic MN, Hodge L, Barber K, et al. Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. Am J Physiol Renal Physiol 2003;285:F1138-48.
34. Miner SE, Al-Hesayen A, Kelly S, et al. L-Arginine transport in the human coronary and peripheral circulation. Circulation 2004;109:1278-83.